Y-mAbs Therapeutics, Inc. (YMAB)
Sep 15, 2025 - YMAB was delisted (reason: acquired by SERB Pharmaceuticals)
8.61
+0.02 (0.23%)
Inactive · Last trade price
on Sep 15, 2025
Y-mAbs Therapeutics Stock Forecast
Stock Price Forecast
The 9 analysts with 12-month price forecasts for Y-mAbs Therapeutics stock had an average target of 13.91, with a low estimate of 7.00 and a high estimate of 23.
Analyst Consensus: Buy
* Price targets were last updated on Aug 6, 2025.
Analyst Ratings
The average analyst rating for Y-mAbs Therapeutics stock from 10 stock analysts was "Buy". This means that analysts believed this stock was likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 2 | 2 |
| Buy | 4 | 4 | 4 | 4 | 4 | 3 |
| Hold | 1 | 1 | 1 | 1 | 4 | 4 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 11 | 11 | 11 | 11 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades $11 → $8.6 | Strong Buy → Hold | Downgrades | $11 → $8.6 | -0.12% | Aug 6, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy → Hold Downgrades $26 → $8.6 | Strong Buy → Hold | Downgrades | $26 → $8.6 | -0.12% | Aug 6, 2025 |
| Jones Trading | Jones Trading | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Aug 5, 2025 |
| Oppenheimer | Oppenheimer | Buy Maintains $20 → $15 | Buy | Maintains | $20 → $15 | +74.22% | May 29, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $12 → $11 | Strong Buy | Maintains | $12 → $11 | +27.76% | May 19, 2025 |
Financial Forecast
Revenue This Year
84.47M
from 87.69M
Decreased by -3.67%
Revenue Next Year
96.27M
from 84.47M
Increased by 13.97%
EPS This Year
-0.84
from -0.67
EPS Next Year
-0.95
from -0.84
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 91.0M | 136.3M | |||
| Avg | 84.5M | 96.3M | |||
| Low | 77.7M | 84.2M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 3.8% | 61.3% | |||
| Avg | -3.7% | 14.0% | |||
| Low | -11.4% | -0.4% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.43 | -0.83 | |||
| Avg | -0.84 | -0.95 | |||
| Low | -1.14 | -1.15 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.